PDF(Pubmed)
Abstract：
This study aimed to evaluate the long-term clinical outcomes of drug-coated drug (DCB) angioplasty for long femoropopliteal lesions in older patients with chronic limb-threatening ischemia (CLTI). In this multi-center retrospective study, we enrolled 119 patients with CLTI due to Trans-Atlantic Inter-Society Consensus (TASCII) C/D femoropopliteal lesions who underwent DCB angioplasty. A total of 119 patients with 122 limbs (TASCII C = 67, 54.9%; TASCII D = 55, 45.1%) were enrolled. At 36-month follow-up, primary patency, assisted primary patency, secondary patency, and freedom from target lesion revascularization were 47.3%, 49.8%, 59.5%, and 62.7%, respectively, and there was a significant improvement over baseline in Rutherford class (P < .001) and ankle-brachial index measurements (P < .001). Complex target lesions (P = .017) and 1 stenosis-free outflow vessel (P = .001) were risk predictors of freedom from clinically driven target lesion revascularization. Complex target lesions (P = .044), diabetes (P = .007), and 1 stenosis-free outflow vessel (P = .003) were risk predictors of restenosis. At 2 months, the ulcer healing rate was 96.3% (26/27). At 36 months, the limb salvage and survival rates were 85.8% and 83.3%, respectively. DCB angioplasty were safe and effective for older patients with CLTI attributable to femoropopliteal TASCII C/D lesions.
摘要：
本研究旨在评估药物涂层药物（DCB）血管成形术治疗老年慢性威胁肢体缺血（CLTI）患者股pop骨长发病变的长期临床疗效。在这项多中心回顾性研究中，我们纳入了119例因跨大西洋社会共识(TASCII)C/D股pop病变而接受DCB血管成形术的CLTI患者.共纳入119例122肢患者（TASCIIC=67，54.9%；TASCIID=55，45.1%）。在36个月的随访中，初级通畅，辅助初级通畅，二级通畅，靶病变血运重建的自由度为47.3%,49.8%,59.5%,和62.7%，分别,卢瑟福级（P<.001）和踝肱指数测量值（P<.001）与基线相比有显著改善。复杂靶病变（P=.017）和1个无狭窄流出血管（P=.001）是临床驱动的靶病变血运重建的风险预测因子。复杂靶病变（P=.044），糖尿病（P=0.007），1个无狭窄流出血管（P=0.003）是再狭窄的风险预测因子。2个月时,溃疡愈合率为96.3%(26/27)。36个月时,保肢率和成活率分别为85.8%和83.3%,分别。DCB血管成形术是安全和有效的老年患者CLTI归因于股popTASCIIC/D病变。
